Artwork

Content provided by STAT. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by STAT or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

34:07
 
Distribuie
 

Manage episode 435741713 series 2986293
Content provided by STAT. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by STAT or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elaine walks us through new study findings that showed Lilly's Zepbound greatly reduced the risk of diabetes. We also discuss a separate study that potentially links GLP-1 drugs to a higher rate of suicidal thoughts.

Lastly, Adam and Elaine interrogate Allison about her deeply reported corporate profile of AI drug developer Recursion. Is all the hype real?

  continue reading

331 episoade

Artwork
iconDistribuie
 
Manage episode 435741713 series 2986293
Content provided by STAT. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by STAT or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elaine walks us through new study findings that showed Lilly's Zepbound greatly reduced the risk of diabetes. We also discuss a separate study that potentially links GLP-1 drugs to a higher rate of suicidal thoughts.

Lastly, Adam and Elaine interrogate Allison about her deeply reported corporate profile of AI drug developer Recursion. Is all the hype real?

  continue reading

331 episoade

Alle Folgen

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință